CJC-1295 DAC - Magnus Pharmaceuticals

Actual product may differ in appearance from image shown

CJC-1295 DAC - Magnus Pharmaceuticals

39.58 €

CJC-1295 can elevate HGH levels in the body for an extended period of time without frequent administration, even though the increases may not be that significant. However, when we compare the cost of CJC-1295 to HGH, CJC-1295 is definitely an appealing peptide hormone. For the effects of CJC-1295 to take effect, the individual should plan on several months of continuous or indefinite use.
CJC-1295_DAC_Magnus_Pharmaceuticals_Leaflet.pdf (38.4kB)

Contents2mg CJC-1295 DAC (VIAL)

About CJC-1295
CJC-1295 is a synthetic growth hormone secretagogue. It specifically belongs to the growth hormone releasing hormone (GHRH) family of drugs. These compounds all mimic the effects of endogenous GHRH, a 44-amino acid hypothalamic peptide hormone that stimulates the release of growth hormone from the pituitary gland. CJC-1295 is actually a very long acting GHRH analog. Whereas native GHRH has a half-life measured in minutes, which reduces its practicality as a therapeutic agent, CJC-1295 is capable of sustained increases in growth hormone and IGF-1 with as little as once per week administration. This drug is used in the fitness community for the support of muscle growth and fat loss, as well as its potential anti-aging properties.

As mentioned, CJC-1295 is a slow acting GHRH analog. Its half-life ranges from 8-10 days in humans. This is due to its high affinity for compartmentalizing with serum albumin, a binding protein. About 90% of injected CJC-1295 winds up bound to albumin, which acts as a distribution vehicle. It provides a slow release of hormone back into free circulation over several weeks. The slow activity of CJC-1295 is reflected in its pharmacokinetic profile. One human study found a single injection (30,60,125, or 250 mcg/kg) to elevate serum growth hormone 2 to 10 fold for up to 6 days. Serum IGF-I levels also rose by 1.5 to 3 fold in this same study, which persisted for up to 2 weeks.

CJC-1295 does not significantly influence peak levels of GH or IGF-I. It also does not appear to influence the number of GH/IGF-1 peak episodes per day (GH is released in pulses, usually 8-10 daily). These measures all remain stable during therapy. We note this is a second study, where researchers did reported a nearly 50% increase in total GH and IGF-1 secretion after administration of 60-90 mcg/kg. Looking very closely at the timing and levels though, they found the increase was in basal secretion.That is, the lows or "trough levels" of hormone that occur in-between GH pulses. With CJC-1295, your "low periods" are significantly higher.

GHRH and ghrelin are the two primary positive regulators of growth hormone secretion in humans. These two hormones are the core focus of drugs of the GHRH and GHRP class, respectively. It is of note that GHRH analogs tend to display more specificity for growth hormone release than GHRPs.That is because endogenous GHRH has less activity in other areas as compared to ghrelin, which seems to influence a more diverse set of systems. Studies examining the pharmacodynamics of CJC-1295 confirm this. They find it has no acute effect on cortisol, prolactin, LH (luteinizing hormone), or TSH (thyroid stimulating hormone). Thus, we consider CJC-1295 a "selective" GH secretagogue, with a low likelihood of spillover side effects.

Note: The research designation for this compound is CJC-1295. Its structure includes a drug affinity complex (DAC). Likewise, referring to this as "CJC-1295 with DAC" is incorrect. All CJC-1295 has DAC. CJC-1295 without DAC is the drug Mod GRF 1-29.

CJC-1295 effects
The primary benefit of CJC-1295 is an increased level of HGH and IGF-1, that affects nearly every cell in the human body from bone and muscle, lungs, skin and even the central nervous system. They are essential in the regulation and promotion of healing and recovery as well as in the regulation of the metabolism.

CJC-1295 can be used for any purpose of performance enhancement, although fat loss may be where it stands out the most. For the off-season athlete looking to pack on more size, CJC-1295 is not a very good choice, when used alone. However, when combined with other performance enhancing drugs, the individual may find he gets more out of them due to the increase in HGH and IGF-1 levels.

For cutting purposes, because of the greatly improved metabolism, the individual should find fat loss to be accelerated and more powerful. He should also find healing and recovery amplified, which is tremendously important during a cutting phase as cutting can slow down recovery due to the necessary calorie restriction.

Finally, the most beneficial effect of CJC-1295 is the overall enhancement in quality of life, including improved recovery, anti-aging effects, healthier skin and improved bone strength. Direct HGH treatment will provide stronger results, however CJC-1295 is a great option for those looking for more natural HGH enhancement. Users of CJC-1295 should also find their immune system is stronger and that sleep is improved.

CJC-1295 administration
CJC-1295 is a water base injectable peptide hormone. Users will apply bacteriostatic water to the dry CJC-1295 powder in order to mix and draw out the desired dose.

Injections can be performed intramuscularly or subcutaneously.

500-1000mcg per week is the standard dosing range with 500mcg two times per week being optimal for most.

CJC-1295 side effects
Common side effects to CJC-1295 include flushing, warmth, dizziness, and transient hypotension following injection. Other common side effects include headache, diarrhea, nausea, and abdominal pain. Many side effects are dose dependent. In studies this drug appeared to be especially well tolerated at doses of 30 and 60 mcg/kg, while more significant side effects were noted with 125 and 250 mcg/kg doses. Also frequently reported are adverse effects typically associated with other types of growth hormone therapy, such as water retention (edema), joint pain (arthralgias), carpal tunnel syndrome, and numbness or tingling in the extremities. Note that the incidence of GFI-related side effects tends to be lower with GHRP therapy as compared to traditional hGFl.This is because GH/IGF-1 release is subject to the limits of endogenous synthesis, and as such the drug is less amenable to overdosing.

With CJC-1295, water retention is possible. High doses are normally responsible for water or fluid retention and can be reduced by dose alterations. Some users may also find they experience a numbing or tingling sensation in their hands or feet during the course of use.

Headaches can also be a side effect of CJC-1295, which is most commonly due to the use of the peptide and drops in blood sugar. Diet adjustments may need to be made during use.

Nausea and diarrhea are also possible yet very unlikely side effects of CJC-1295.